Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2033675 | 0.98 | L3MBTL1 (0.49) | L3MBTL1TDP1ALDH1A1ABCB1KEAP1 | |
| SCHEMBL27207840 | 0.89 | ALOX5 (0.51) | L3MBTL1TDP1SMN1; SMN2ALOX5HDAC3 | |
| SCHEMBL27207879 | 0.81 | NAMPT (0.49) | L3MBTL1ALDH1A1MAPTSMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL27207834 | 0.80 | NAMPT (0.48) | ALDH1A1SMN1; SMN2KMT2ACYP4F2CYP4A11 | |
| SCHEMBL3248618 | 0.80 | ALDH1A1 (0.50) | TDP1ALDH1A1KEAP1MAPTSMN1; SMN2 | |
| SCHEMBL506200 | 0.80 | KMT2A (0.43) | L3MBTL1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13015860 | 0.79 | L3MBTL1 (0.52) | L3MBTL1TDP1ALDH1A1ABCB1KEAP1 | |
| Hydrochloric Acid SCHEMBL3248613 | 0.78 | CMA1 (0.49) | TDP1ALDH1A1KEAP1MAPTKMT2A | |
| Bromide SCHEMBL9729336 | 0.78 | KMT2A (0.42) | L3MBTL1ALDH1A1SMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL506846 | 0.78 | KMT2A (0.42) | L3MBTL1ALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667265-A | CGAS-inhibiting triazolopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-9522194-B2 | Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522194-B2 | Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150044238-A1 | METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150044238-A1 | METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8871720-B2 | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871720-B2 | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8450362-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450362-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450362-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2011076687-A1 | PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-30 | — | — | WO | disclosed |
| EP-2222637-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-02 | — | — | US | disclosed |
| WO-2009079392-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009079392-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | SEATTLE GENECTICS, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | SEATTLE GENECTICS, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2007008848-A2 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | MMAB, PTMS, CAD | L3MBTL1 76/4885TDP1 1913/4885ALDH1A1 3118/4885 |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | L3MBTL1 2828/4885TDP1 4463/4885ALDH1A1 4249/4885 |
| US-20150044238-A1 | METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | MARS1, PTMS, L3MBTL1 | L3MBTL1 3/4885TDP1 1103/4885ALDH1A1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.